Q-omics provides the consensus-scored EMB profile across patient tissues and cancer cell-line models. EMB expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EMB is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, EMB RNA expression shows 22,812 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where EMB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EMB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EMB survival associations across molecular data types. EMB RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EMB RNA expression–survival associations across cancer types. High EMB expression shows unfavorable associations in UVM and KIRP, but favorable associations in MESO, SKCM, ACC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for EMB RNA expression.
This table summarizes EMB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for EMB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EMB shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, LUAD, CHOL and STAD. The KIRC box plot shows higher EMB RNA expression in tumor versus normal tissue (log2 FC = +1.709, t-test p < 0.001).
This table shows molecular features associated with EMB in patient tissues and cancer cell lines. In patient samples, EMB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EMB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
